Therapeutic Management of Systemic Vasculitis with Renal Involvement
The correct answers are (c) and (e): induction therapy for systemic vasculitis with renal involvement requires high-dose corticosteroids combined with either cyclophosphamide or rituximab during the acute phase.
Induction Therapy (Acute Phase)
The 2024 KDIGO guidelines establish the standard approach for organ-threatening or life-threatening AAV with renal involvement 1:
Combination therapy is mandatory - high-dose corticosteroids PLUS an immunosuppressant agent (either cyclophosphamide or rituximab). Corticosteroids alone (option b) are insufficient and contraindicated for severe disease 2, 1.
Specific Induction Regimens:
Corticosteroid dosing 1:
- Initial pulse: 1,000 mg methylprednisolone IV for 1-3 days
- Followed by oral prednisolone (weight-based):
- <50 kg: 50 mg/day week 1
- 50-75 kg: 60 mg/day week 1
75 kg: 75 mg/day week 1
- Rapid taper over 5 months to 5 mg/day
Immunosuppressant options 1:
Cyclophosphamide:
- Oral: 2 mg/kg/day for 3-6 months (reduce for age >60 years and GFR <30)
- IV: 15 mg/kg at weeks 0,2,4,7,10,13
Rituximab: 375 mg/m² weekly × 4 weeks
Both agents have equivalent efficacy for remission induction 3, 4. Rituximab is preferred for patients with childbearing potential, prior cyclophosphamide exposure, or relapsing disease 2, 1.
Why Azathioprine is Wrong for Acute Phase (Option d)
Azathioprine has NO role in induction therapy 1. It is exclusively a maintenance agent used AFTER remission is achieved. Using azathioprine during the acute phase would result in inadequate disease control and progression to end-stage renal disease.
Maintenance Therapy
After achieving remission (typically 3-6 months), transition to maintenance therapy 1:
Preferred agents:
- Rituximab: 500 mg IV every 6 months for 18-48 months (superior to azathioprine for preventing relapses) 1
- Azathioprine: 1.5-2 mg/kg/day PLUS low-dose glucocorticoids (5-7.5 mg/day) for 24-48 months 1
Duration should be individualized based on relapse risk factors: PR3-ANCA positivity, lung involvement, persistent ANCA positivity, and history of relapse 1.
Role of ACE Inhibitors (Option a)
ACE inhibitors are NOT primary vasculitis therapy - they serve as adjunctive renoprotective agents for managing proteinuria and hypertension, but have no immunosuppressive effect on the underlying vasculitis 5. They do not constitute "therapeutic management" of the vasculitis itself.
Critical Treatment Principles
Plasma exchange considerations 1:
- Consider for severe AKI (creatinine >3.4 mg/dL or dialysis-dependent)
- Consider for diffuse alveolar hemorrhage with hypoxemia
- Reduces risk of ESRD at 3 and 12 months 4
Common pitfalls to avoid:
- Never use corticosteroids alone for severe disease
- Never use azathioprine for induction
- Never delay treatment while awaiting biopsy if clinical suspicion is high
- Adjust cyclophosphamide doses for age and renal function to prevent toxicity 1
The evidence strongly supports that options (c) and (e) represent correct therapeutic approaches, with combination immunosuppression being the cornerstone of treatment for systemic vasculitis with renal involvement 2, 1, 3.